The present invention is directed to novel cyclic amines which inhibit the P2X
7
receptor.
本发明涉及抑制P2X7受体的新型环胺化合物。
2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS
申请人:Siegel Stephan
公开号:US20100105663A1
公开(公告)日:2010-04-29
The invention relates to substituted indazoles and methods for production thereof and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, especially of cardiovascular diseases, preferably of thromboembolic diseases.
2-(CYCLIC AMINEETHYL)BENZAMIDE DERIVATIVES AS P2X7 INHIBITORS
申请人:MindImmune Therapeutics, Inc.
公开号:EP3536689A1
公开(公告)日:2019-09-11
The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
本发明涉及新型环胺,可抑制 P2X7 受体。
SNAr or Sulfonylation? Chemoselective Amination of Halo(het)arene Sulfonyl Halides for Synthetic Applications and Ultralarge Compound Library Design
作者:Vasyl Naumchyk、Vladyslav A. Andriashvili、Dmytro S. Radchenko、Dmytro Dudenko、Yurii S. Moroz、Andrey A. Tolmachev、Serhii Zhersh、Oleksandr O. Grygorenko
DOI:10.1021/acs.joc.3c02636
日期:2024.3.1
The chemoselectivity of halo(het)arene sulfonyl halide aminations is studied thoroughly under parallel synthesis conditions, and the scope and limitations of the method are established. It is shown that SNAr-reactive sulfonyl halides typically undergo sulfonamide synthesis during the first step; the second amination is also possible provided that the SNAr-active center is sufficiently reactive. On
在平行合成条件下深入研究了卤代(杂)芳烃磺酰卤胺化物的化学选择性,并确定了该方法的范围和局限性。结果表明, SN Ar反应性磺酰卤通常在第一步中进行磺酰胺合成;如果SN Ar活性中心具有足够的反应性,则第二次胺化也是可能的。相反,带有芳基化部分的磺酰氟在适当的控制下在后一个反应中心发生选择性转化。进一步的硫-氟化物交换(SuFEx)也是可能的,这对于某些磺酰卤类特别有价值。开发的两步并行双胺化方案提供了对 66.7 亿个化合物的合成可处理 REAL 型化学空间的访问(预期合成成功率 76%)。